Escalating every six weeks instead of four: what I observed over eight months — one year on

Answering the question the opening post raises rather than the one it answers.

Reaching a dose and staying there for a year: the question of whether a stable dose remains effective over years is mostly answered by the withdrawal trials and by real-world reports. The dose does not seem to stop working, but the longest trials are not indefinitely long.

Post #4 describes the usual case. This is about the unusual one.

Dose and effect are not linear across the studied range for every compound in this class. Assuming a doubled dose gives a doubled effect is the reasoning error behind most disappointment.

One more caveat and then I will stop qualifying: the sample selected itself.

Taking post #11 at face value and following it one step further.

Two things can be true about Escalating every six weeks instead at once: the mechanism is plausible and the evidence for the size of the effect is thin. Most of the argument here is people defending the first against attacks on the second.

A titration plan written down in advance is easier to stick to and easier to abandon deliberately. An improvised one becomes a series of decisions made on the worst day of each week.

I would want a second opinion before relying on that.

On post #15 — agreed on the reasoning, with one qualification.

On Escalating every six weeks instead: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here including this one.

The four-week escalation interval is a convention from the pivotal trials, not a pharmacological constant. The pharmacological argument is that with a week-long half-life, four weeks approaches steady state and you can assess the dose fairly. That is an argument for not going faster. It is not an argument against going slower.

On post #40 — agreed on the reasoning, with one qualification.

Small methodological point on Escalating every six weeks instead: repeating a measurement is cheap and resolves most of what is being argued about here at no cost to anyone.

Dose equivalence between different incretin analogues is a weak concept. The molecules differ in structure, half-life, receptor selectivity, and in what has been studied clinically. One mg of semaglutide is not equivalent to one mg of something else in any meaningful sense.

Take the reasoning and check the arithmetic; I do not always get it right.

Post #51 describes the usual case. This is about the unusual one.

Where the Escalating every six weeks instead discussion usually stalls is that nobody wants to say "I do not know" and everyone is willing to say "it varies". Those are the same sentence with different clothes on.